Clinical trial · Interventional
STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma
A Two-Stage Trial of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Metastatic Melanoma
NCT00084214CI-TRIAL-00013961completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is designed to assess the efficacy of a weekly treatment regimen of STA-4783 and paclitaxel in comparison to paclitaxel alone on tumor response in metastatic melanoma patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Paclitaxel | Drug | Paclitaxel | ALIAS |
| STA-4783 | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * M or F 18 or older with histologically confirmed metastatic (Stage IV) melanoma of cutaneous origin * ECOG performance status of greater than or equal to 2 * Measurable disease per RECIST criteria * Received no more than 1 regimen of prior chemotherapy (unlimited immunotherapy regimens are allowed) * At least 4 weeks have passed since last chemotherapy or immunotherapy * At least 2 weeks have passed since last radiotherapy. * Life expectancy of greater than 12 weeks * Clinical lab values within protocol parameters Exclusion Criteria: * Female patients pregnant or lactating * Female patients of childbearing potential not using or not willing to use effective contraception * Presence of a second malignancy other than nonmelanoma skin cancer * Presence of a clinically significant and uncontrolled infection * Presence of clinically significant arrythmias * Presence of serious concurrent illness or other conditions that do not permit adequate follow-up and compliance with protocol * History of severe hypersensitivity reactions to taxanes * Use of any investigational agents within 4 weeks prior to the first dose of study drug
References
Publications (0)
Data not yet available
No reference posted for this study.